On September 24, 2019, the U.S. Food and Drug Administration (FDA) approved the first live, non-replicating vaccine for prevention of smallpox and monkeypox disease in adults 18 years of age and older determined to be at high risk for smallpox or monkeypox infection.
While there is currently no vaccine available from the manufacturer for use, the Department of Defense and other government partners are engaged in robust discussions regarding future deployment of this vaccine within the military.
Further information will be provided once available.